Piperacetazine
Clinical data | |
---|---|
Trade names | Actazine, Quide, Psymod |
AHFS/Drugs.com | International Drug Names |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.021.194 |
Chemical and physical data | |
Formula | C24H30N2O2S |
Molar mass | 410.58 g·mol−1 |
3D model (JSmol) | |
| |
|
Piperacetazine (Quide) is an antipsychotic prodrug, most notably used for schizophrenia.[1] It is a phenothiazine derivative. Based on clinical trial data, it appears to have similar efficacy as chlorpromazine. However, very little research has been done since the 1970s, and it is not a commonly used drug today.[2]
Side effects
The side effect profile of piperacetazine is similar to that of other typical antipsychotics. The most common side effects of piperacetazine are dizziness, drowsiness, fainting, orthostatic hypotension, and extrapyramidal symptoms. Less common side effects include nausea, vomiting, bradycardia, euphoria, and headache. Rare side effects include leukopenia, thrombocytopenia, galactorrhea, amenorrhea, seizures, urinary retention, and jaundice.[2]
References
- ^ Rada RT, Donlon PT (February 1974). "Piperacetazine in ambulatory chronic schizophrenic patients". Current Therapeutic Research, Clinical and Experimental. 16 (2): 124–129. PMID 4156665.
- ^ a b Eslami Shahrbabaki M, Dehnavieh R, Vali L, Sharafkhani R (October 2018). "Chlorpromazine versus piperacetazine for schizophrenia". The Cochrane Database of Systematic Reviews. 10 (10): CD011709. doi:10.1002/14651858.CD011709.pub2. PMC 6517193. PMID 30378678.
See what we do next...
OR
By submitting your email or phone number, you're giving mschf permission to send you email and/or recurring marketing texts. Data rates may apply. Text stop to cancel, help for help.
Success: You're subscribed now !